Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Daniel E. Bergsagel"'
Autor:
Daniel E. Bergsagel
Publikováno v:
European Journal of Haematology. 43:117-123
Reports of 13 prospective, randomized clinical trials comparing standard treatment with melphalan and prednisone (MP) versus various drug combinations in the treatment of myeloma patients are presented. These studies reveal that patients with Durie-S
Autor:
Rolla Edward Park, R.M. Rifkin, Sundar Jagannath, Martin M. Oken, Martin Perlman, Brian G.M. Durie, Kenneth C. Anderson, Daniel E. Bergsagel, Robert W. Dubois, Robert Peter Gale, William M. Audeh, Marvin J. Stone, Robert A. Kyle
Publikováno v:
Leukemia & Lymphoma. 33:511-519
There is controversy whether high-dose therapy and a bone marrow autotransplant or conventional chemotherapy is a better treatment for newly diagnosed multiple myeloma. Data from 1 comparative study and 1 randomized trial provide insufficient subject
Autor:
Daniel E. Bergsagel
Publikováno v:
Baillière's Clinical Haematology. 8:783-794
Plasma cell neoplasms often present in an asymptomatic, stable phase. Treatment should not be started until manifestations, such as bone pain, increased susceptibility to infections, renal failure, anaemia and weight loss, announce that the disease h
Autor:
Andrew R. Belch, D. Johnston, George P. Browman, J. Skillings, Joseph L. Pater, Kenneth S. Wilson, Daniel E. Bergsagel
Publikováno v:
British Journal of Haematology. 82:555-559
The purpose of this single arm phase II study was to test a modified version of the three drug combination vincristine, adriamycin and dexamethasone (m-VAD), in which intravenous vincristine (0.4 mg/d) and adriamycin (9 mg/m2 per day) infusions are a
Autor:
Daniel E. Bergsagel
Publikováno v:
Annual Review of Medicine. 42:167-178
Plasma cell myeloma results from malignant transformation in an early hemopoietic precursor cell. The disease progresses from an asymptomatic stable phase through a symptomatic phase to a terminal acute phase marked by aggressive cell growth and marr
Autor:
Robert A. Kyle, Daniel E. Bergsagel
Publikováno v:
Biology and Management of Multiple Myeloma ISBN: 9781617371431
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4d310686f4cf6d2a0d1c6fca8503eaf6
https://doi.org/10.1007/978-1-59259-817-5_1
https://doi.org/10.1007/978-1-59259-817-5_1
Autor:
Daniel E. Bergsagel
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 116:104-105
Chronic myelogenous leukemia (CML) is a clonal hemopathy characterized by excessive proliferation of hemopoietic precursor cells and gross expansion of the myeloid cell mass. Recent advances in the molecular biology of the Philadelphia (Ph') chromoso
Autor:
Daniel E. Bergsagel
Publikováno v:
Cancer Treatment Reviews. 15:15-20
Autor:
Daniel E. Bergsagel
Publikováno v:
Clinics in Haematology. 11:221-234